myelodysplastic syndromes (MDS) | Page 15 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease

Author(s): 
Cerchione C, Cerciello G, Avilia S, Pepa RD, Pugliese N, Picardi M, Catalano L, Pane F
Primary Author: 
Cerchione C
Journal Title: 
Blood Transfus
Original Publication Date: 
Oct 2016

mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">No abstract available.

Bone Marrow Diseases: 

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Author(s): 
Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S
Primary Author: 
Montalban-Bravo G
Journal Title: 
Leukemia
Original Publication Date: 
Oct 2016

Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a

Bone Marrow Diseases: 

BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine

Author(s): 
Lazarini M, Machado-Neto JA, Duarte AD, Pericole FV, Vieira KP, Niemann FS, Alvarez M, Traina F, Saad ST
Primary Author: 
Lazarini M
Journal Title: 
Haematologica
Original Publication Date: 
Nov 2016

mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">No abstract available.

Bone Marrow Diseases: 

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes

Author(s): 
Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR; from the Center for International Blood and Marrow Trans
Primary Author: 
Artz AS
Journal Title: 
Haematologica
Original Publication Date: 
Nov 2016

We sought to confirm the prognostic importance of simple clinically available biomarkers of C-reactive protein, serum albumin, and

Bone Marrow Diseases: 

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Author(s): 
Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Leukemia
Original Publication Date: 
Nov 2016

The Revised

Bone Marrow Diseases: